EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays

Chelva Janarthanam, Christina D Orrú, Andrew G Hughson, David Holzinger, Keenan Taylor, Anumantha G Kanthasamy, Byron Caughey, Roland G Heym, Charles H Adler, Holly A Shill, Shyamal Mehta, Erika Driver-Dunckley und 9 weitere

Journal of Neuropathology & Experimental Neurology · 2026

DOI: 10.1093/jnen/nlag048 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2026. Verfasst von Chelva Janarthanam und 20 weiteren Autor:innen. Beteiligte Einrichtung: Isakson Center for Neurological Disease Research, The University of Georgia, Athens, GA, United States. Hauptthemen laut MEDLINE: Lewy Body Disease, alpha-Synuclein, Skin, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, NIA NIH HHS, US National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin biopsies analyzed with α-synuclein seed amplification assays (SAAs) are a simple way to clinically interrogate the presence of α-synuclein aggregates. We determined the accuracy of skin biopsy SAA in predicting the clinical diagnoses of Parkinson disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB). Blinded SAAs were performed in 3 independent laboratories. Subjects diagnosed with PD, PDD and DLB were analyzed together as group 1, clinically unaffected subjects as group 2 and those with risk factors for LBD as group 3. Punch biopsies were taken from the posterior neck and analyzed by the 3 labs in 6 separate SAAs. Pairwise agreement between labs and assays ranged from excellent (kappa 0.82) to moderate (kappa 0.40-0.68). Sensitivity across assays ranged between 50.0% and 61.3%; specificity ranged between 68.6% and 100%. Comparisons of group 1 vs group 2 produced the greatest specificities, between 77.3% and 100%. In 17 cases that subsequently came to autopsy, 93% of SAAs were positive in those at the neocortical LBD stage but in only <10% of those at lower stages. Skin biopsy α-synuclein SAA may be useful as a diagnostic and progression biomarker in Lewy body dementia clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body Diseasealpha-SynucleinSkinParkinson DiseaseHumansFemaleBiopsyAgedMaleAged, 80 and overSensitivity and Specificity

Stichwörter der Autor:innen

Lewy body dementiaParkinson diseasebiomarkerclinical trialdiagnosisprogression

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Isakson Center for Neurological Disease Research, The University of Georgia, Athens, GA, United States.
  • Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, MT, United States.
  • AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Ludwigshafen, Germany.
  • AbbVie Bioresearch Center, Biotherapeutics and Genetic Medicine Technologies, Worcester, MA, United States.
  • Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, United States.
  • Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, United States.

ORCID-Profile: Thomas G Beach

Förderung

  • Division of Intramural Research of the National Institute of Allergy and Infectious Diseases
  • NIA NIH HHS
  • US National Institute of Neurological Disorders and Stroke
  • NINDS NIH HHS
  • Intramural NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Janarthanam, C., Orrú, C. D., Hughson, A. G., Holzinger, D., Taylor, K., Kanthasamy, A. G., Caughey, B., Heym, R. G., Adler, C. H., Shill, H. A., Mehta, S., Driver-Dunckley, E., Ho, A. H., Choudhury, P., Shprecher, D. R., Belden, C. M., Atri, A., Zhang, N., Chen, K., …, & Beach, T. G. (2026). Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlag048

Vancouver

Janarthanam C, Orrú CD, Hughson AG, Holzinger D, Taylor K, Kanthasamy AG, et al. Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays. Journal of Neuropathology & Experimental Neurology. 2026. doi:10.1093/jnen/nlag048

BibTeX
@article{Janarthanam2026,
  author = {Janarthanam, Chelva and Orrú, Christina D and Hughson, Andrew G and Holzinger, David and Taylor, Keenan and Kanthasamy, Anumantha G and Caughey, Byron and Heym, Roland G and Adler, Charles H and Shill, Holly A and Mehta, Shyamal and Driver-Dunckley, Erika and Ho, Andrew H and Choudhury, Parichita and Shprecher, David R and Belden, Christine M and Atri, Alireza and Zhang, Nan and Chen, Kewei and Serrano, Geidy E and Beach, Thomas G},
  title = {Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2026},
  doi = {10.1093/jnen/nlag048}
}
Kostenlos starten →